Nasdaq-listed pharmaceutical company Artelo launches Solana reserve asset strategy

According to Foresight News, clinical-stage pharmaceutical company Artelo Biosciences (NASDAQ: ARTL) announced the completion of an over-the-counter private equity financing of $9.475 million, which will be used to launch a digital asset reserve strategy with Solana (SOL) as its core. The company became the first listed pharmaceutical company to include SOL in reserve assets.

The private placement includes issuance of common stock (or advance warrants) at $10.45 per share, and two three-year warrants with exercise prices of $10.20 and $50, respectively. The transaction is expected to close on August 5, 2025.

Disclaimer: The views in this article only represent the author's personal views and do not constitute investment advice of this platform. This platform does not make any guarantees for the accuracy, completeness, originality and timeliness of article information, nor is it liable for any losses caused by the use or trust in article information.